

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE



Atty. Docket: PALMER=1

re Application of: ) Conf. No.: 1664  
Stephen PALMER, et al ) Art Unit: 1756  
Appn. No.: 10/014,812 ✓ ) Examiner:  
Filed: December 14, 2001 ✓ ) Washington, D.C.  
For: METHOD OF INDUCING ) May 9, 2002  
OVULATION ✓ )

INFORMATION DISCLOSURE STATEMENT [IDS]

Honorable Commissioner of Patents and Trademarks  
Washington, D.C. 20231

Sir :

This Information Disclosure Statement is submitted in accordance with 37 CFR §§1.97, 1.98, and it is requested that the information set forth in this statement and in the listed documents be considered during the pendency of the above-identified application, and any other application relying on the filing date of the above-identified application or cross-referencing it as a related application.

1. This IDS should be considered, in accordance with 37 CFR §1.97, as it is filed before the mailing date of a first office action on the merits.

2. In accordance with 37 CFR §1.98, this IDS includes a list (e.g., form PTO-1449) of all patents, publications, or other information submitted for consideration by the office, either incorporated into this IDS or as an attachment hereto. A copy of each document listed is attached.

#5  
6/25/02  
RECEIVED  
JUN 24 2002  
TECH CENTER 1600/2900

RECEIVED  
MAY 13 2002  
TC 1700


3. No explanation of relevance is necessary for documents in the English language (see reply to Comments 67 and 68 in the preamble to the final rules; 1135 OG 13 at 20).

4. In accordance with 37 CFR §§1.97(g) and (h), the filing of this IDS should not be construed as a representation that a search has been made or that information cited is, or is considered to be, material to patentability as defined in §1.56 (b), or that any cited document listed or attached is (or constitutes) prior art. Unless otherwise indicated, the date of publication indicated for an item is taken from the face of the item and Applicant(s) reserves the right to prove that the date of publication is in fact different.

Respectfully submitted,

BROWDY AND NEIMARK  
Attorneys for Applicant(s)

By:

  
Sheridan Neimark  
Reg. No. 20,520

SN:wlm:btd

624 Ninth Street, N.W., Suite 300  
Washington, D.C. 20001-5303  
Telephone: (202) 628-5197  
Facsimile: (202) 737-3528

F:\S\Se\Palmer1\Pto\Ids.doc

#5

Substitute for form 1449A/PTO				Complete if Known	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>				Application Number	10/014,812
				Filing Date	December 14, 2001
				First Named Inventor	Stephen PALMER et al.
				Group Art Unit	1756
				Confirmation No.	1664
(use as many sheets as necessary)				Attorney Docket Number	PALMER=1
Sheet	1	of	3		

RECEIVED

RECEIVED  
MAY 13 2002  
TC 1100

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

2

of

3

Complete if Known

Application Number	10/014,812
Filing Date	December 14, 2001
First Named Inventor	Stephen PALMER et al.
Group Art Unit	1756
Confirmation No.	1664

Attorney Docket Number PALMER=1

TECH CENTER 1600/2900

JUN 24 2002

RECEIVED

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	
9	AS	BRITO, et al, "Type 4 Phosphodiesterase Inhibitors and their Potential in the Treatment of Inflammatory Disease", Chapter 12, <u>Emerging Drugs: The Prospect for Improved Medicines</u> , Ashley Publications Ltd., ISSN 1361-9195: 2:249-268 (1997).	<sup>2</sup>
9	AT	CONTI, M., "Phosphodiesterases and Cyclic Nucleotide Signaling in Endocrine Cells", <u>Molecular Endocrinology</u> , 14(9):1317-1327 (2000).	
11	AU	COOKE, G.M. "Differential Effects of Trilostane and Cyanoketone on the 3 Beta-Hydroxysteroid Dehydrogenase-Isomerase Reactions in Androgen and 16-Androstene Biosynthetic Pathways in the Pig Testis", <u>J Steroid Biochem Mol Biol</u> 58:1 95-101 (1996).	
6	AV	M. FILICORI, "Ovulation Induction: Gonadotropin-Releasing Hormone and Its Agonists", <u>Reproductive Endocrinology, Surgery, and Technology</u> , Volume 2, Chapter 61, Lippincott-Raven Publishers, Philadelphia (1996).	
8	AW	S. FRANKS et al., "Ovulation Induction: Gonadotropins", <u>Reproductive Endocrinology, Surgery, and Technology</u> , Vol. 2, Chapter 60, Lippincott-Raven Publishers, Philadelphia (1996).	
7	AX	HASSAN, et al, "Phosphodiesterase Inhibitor Improved Responsiveness to Gonadotropins In Low Responders", <u>Fertility &amp; Sterility</u> , S249: 489, Alexandria ICSI-IVF Center, Alexandria, Egypt.	
2	AY	KARLSSON, et al. "Pulmonary-Allergy, Dermatological, Gastrointestinal & Arthritis", <u>Exp. Opin. Ther. Patents</u> , Ashley Publications Ltd., ISSN 1354-3776, 7(9):989-1003 (1997).	
	AZ	MOVSESIAN, M., "Therapeutic Potential of Cyclic Nucleotide Phosphodiesterase Inhibitors in Heart Failure", <u>Exp. Opin. Invest. Drugs</u> , Ashley Publications Ltd., ISSN 1354-3784, 9(5):963-973 (2000).	
6	BA	NORMAN, P., "PDE4 Inhibitors 1999", <u>Exp. Opin. Ther. Patents</u> , Ashley Publications Ltd., ISSN 1354-3776, 9(6): 1101-1118 (1999).	
7	BB	O'DONNELL, J., "William Harvey Research Conference on PDE Inhibitors: Drugs with an Expanding Range of Therapeutic Uses", <u>Exp. Opin. Invest. Drugs</u> , Ashley Publications Ltd., ISSN 1354-3784, 9(3):621-625 (2000).	
6	BC	"Patent Evaluation: Nicotinamide Derivatives as Selective Inhibitors of PDE4: Pfizer Products, Inc. WO9845268", <u>Exp. Opin. Ther. Patents</u> , Ashley Publications Ltd., ISSN 1354-3776, 9(4):481-485 (1999).	
7	BD	"Patent Evaluation: Pulmonary-Allergy, Dermatological, Gastrointestinal & Arthritis: Phosphodiesterase 4 Inhibitors: Celltech Therapeutics Ltd.: WO9723460 & WO9723461", <u>Exp. Opin. Ther. Patents</u> , Ashley Publications Ltd., ISSN 1354-3776, 7(11):1355-1357 (1997).	
7	BE	"Patent Evaluation: Substituted Indazole Derivatives and their use as Inhibitors of PDE4 and the Production of Tumour Necrosis Factor: Pfizer, Inc.: WO9742174", <u>Exp. Opin. Ther. Patents</u> , Ashley Publications Ltd., ISSN 1354-3776, 8(8):1053-1056 (1998).	

RECEIVED  
MAY 13 2002  
TC 100Examiner  
SignatureDate  
Considered

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449A/PTO				Complete if Known	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(use as many sheets as necessary)</i>				Application Number	10/014,812
				Filing Date	December 14, 2001
				First Named Inventor	Stephen PALMER et al.
				Group Art Unit	1756
				Confirmation No.	1664
Sheet	3	of	3	Attorney Docket Number	PALMER-1

RECEIVED

**OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
2	BF	"Patent Evaluation: A Heterogeneous Collection of Novel Phosphodiesterase Type 4 Inhibitors", <u>Exp. Opin. Ther. Patents</u> , Ashley Publications Ltd., ISSN 1354-3776, 8(11):1529-1536 (1998).	
11	BG	"Patent Evaluation: Benzofuran and Quinoline Carboxamides and Quinoline Sulfonamides as TNF Inhibitors and as PDE4 Inhibitors: Chiroscience Ltd.: WO9744337, WO9744036, WO9744322", <u>Exp. Opin. Ther. Patents</u> , Ashley Publications Ltd., ISSN 1354-3776, 8(7):899-905 (1998).	
4	BH	R. PHILOSOPHIE et al., "Gonadotropin-Induced Ovulation", <u>Reproductive Endocrinology, Surgery, and Technology</u> , Vol. 1, Chapter 54, Lippincott-Raven Publishers, Philadelphia (1996).	
7	BI	SHETTY, et al. "Effect of Estrogen Deprivation on the Reproductive Physiology of Male and Female Primates", <u>J Steroid Biochem Mol Biol</u> 61:3-6, 157-166 (1997).	
4	BJ	VAN LOON, "In utero exposure to gonadotrophins", <u>Female Infertility Therapy Current Practice</u> , Chapter 1, SHOHAM, et al. (Eds.), Martin Dunitz Ltd., London (1999)	
1	BK	SHUGHRUE et al., "Regulation of Progesterone Receptor Messenger Ribonucleic Acid in the Rat Medial Preoptic Nucleus by Estrogenic and Antiestrogenic Compounds: an in situ hybridization study", <u>Endocrinology</u> , 138:12, 5476-5484 (1999).	
3	BL	A. TSAFRIRI et al., "Ovulation", <u>Reproductive Endocrinology, Surgery, and Technology</u> , Vol. 1, Chapter 11, Lippincott-Raven Publishers, Philadelphia (1996).	
8	BM	TURNER, et al., "Effect of Chronic Administration of an Aromatase Inhibitor to Adult Male Rats on Pituitary and Testicular Function and Fertility", <u>J Endocrinol</u> , 164:2, 225-238 (2000).	
	BN	CHAPPEL et al., "Basic Knowledge About Recombinant Gonadotrophic Hormone Production", <u>Female Infertility Therapy Current Practice</u> , Chapter 9, SHOHAM, et al. (Eds.), Martin Dunitz Ltd., London (1999)	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.